Expression of S100A4, ephrin-A1 and osteopontin in non-small cell lung cancer

BMC Cancer

Ane Kongsgaard Rud²  Marius Lund-Iversen¹  Gisle Berge²  Odd Terje Brustugun³  Steinar K Solberg⁴  Gunhild M Mælandsmo⁵  Kjetil Boye³ 

[1] Department of Pathology, The Norwegian Radium Hospital, Oslo University Hospital, PO Box 4953, Nydalen, NO-0424, Oslo, Norway

[2] Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, PO Box 4953, Nydalen, NO-0424, Oslo, Norway

[3] Department of Oncology, The Norwegian Radium Hospital, Oslo University Hospital, PO Box 4953, Nydalen, NO-0424, Oslo, Norway

[4] Department of Cardiovascular and Thoracic Surgery, Rikshospitalet, Oslo University Hospital, PO Box 4953, Nydalen, NO-0424, Oslo, Norway

[5] Department of Pharmacy, Faculty of Health Sciences, University of Tromsø, 9037, Tromsø, Norway

关键词: Immunohistochemistry;    NSCLC;    Osteopontin;    Ephrin-A1;    S100A4;   

Others  :  1080275
DOI  :  10.1186/1471-2407-12-333

 received in 2012-02-16, accepted in 2012-07-27,  发布年份 2012

【 摘 要 】

Background

The metastasis-promoting protein S100A4 induces expression of ephrin-A1 and osteopontin in osteosarcoma cell lines. The aim of this study was to investigate S100A4-mediated stimulation of ephrin-A1 and osteopontin in non-small cell lung cancer (NSCLC) cell lines, and to characterize the expression of these biomarkers in primary tumor tissue from NSCLC patients.

Methods

Four NSCLC cell lines were treated with extracellular S100A4, and ephrin-A1 and osteopontin expression was analyzed by real time RT-PCR and Western blotting. Immunohistochemical staining for S100A4, ephrin-A1 and osteopontin was performed on tissue microarrays containing primary tumor samples from a cohort of 217 prospectively recruited NSCLC patients, and associations with clinicopathological parameters were investigated.

Results

S100A4 induced ephrin-A1 mRNA and protein expression in adenocarcinoma, but not in squamous carcinoma cell lines, whereas the level of osteopontin was unaffected by S100A4 treatment. In primary tumors, moderate or strong immunoreactivity was observed in 57% of cases for cytoplasmic S100A4, 46% for nuclear S100A4, 86% for ephrin-A1 and 77% for osteopontin. Interestingly, S100A4 expression was associated with ephrin-A1 also in vivo, but there was no association between S100A4 and osteopontin. Expression levels of S100A4 and ephrin-A1 were significantly higher in adenocarcinomas compared to other histological subtypes, and S100A4-positive tumors were smaller and more differentiated than tumors without expression.

Conclusions

Our findings suggest that S100A4, ephrin-A1 and osteopontin are involved in the biology of NSCLC, and further investigation of their potential use as biomarkers in NSCLC is warranted.

【 授权许可】

   
2012 Rud et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Figures. 2nd edition. American Cancer Society, Atlanta, GA; 2007.
• [2]Cancer in Norway. Cancer Registry of Norway, Oslo,Norway; 2009.
• [3]Kinch MS, Moore MB, Harpole DH: Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival. Clin Cancer Res 2003, 9:613-618.
• [4]Boye K, Maelandsmo GM: S100A4 and metastasis: a small actor playing many roles. Am J Pathol 2010, 176:528-535.
• [5]Takenaga K, Nakamura Y, Endo H, Sakiyama S: Involvement of S100-related calcium-binding protein pEL98 (or mts1) in cell motility and tumor cell invasion. Jpn J Cancer Res 1994, 85:831-839.
• [6]Takenaga K, Nakamura Y, Sakiyama S: Expression of antisense RNA to S100A4 gene encoding an S100-related calcium-binding protein suppresses metastatic potential of high-metastatic Lewis lung carcinoma cells. Oncogene 1997, 14:331-337.
• [7]De Petris L, Orre LM, Kanter L, Pernemalm M, Koyi H, Lewensohn R, Lehtio J: Tumor expression of S100A6 correlates with survival of patients with stage I non-small-cell lung cancer. Lung Cancer 2009, 63:410-417.
• [8]Jung EA, Cho HD, Lee J-H, Oh M-H: Clinicopathological Significance of S100A4 Expression in Non-small Cell Lung Carcinomas. The Korean Journal of Pathology 2010, 44:477-482.
• [9]Kimura K, Endo Y, Yonemura Y, Heizmann CW, Schafer BW, Watanabe Y, Sasaki T: Clinical significance of S100A4 and E-cadherin-related adhesion molecules in non-small cell lung cancer. Int J Oncol 2000, 16:1125-1131.
• [10]Matsubara D, Niki T, Ishikawa S, Goto A, Ohara E, Yokomizo T, Heizmann CW, Aburatani H, Moriyama S, Moriyama H, et al.: Differential expression of S100A2 and S100A4 in lung adenocarcinomas: clinicopathological significance, relationship to p53 and identification of their target genes. Cancer Sci 2005, 96:844-857.
• [11]Tsuna M, Kageyama S, Fukuoka J, Kitano H, Doki Y, Tezuka H, Yasuda H: Significance of S100A4 as a prognostic marker of lung squamous cell carcinoma. Anticancer Res 2009, 29:2547-2554.
• [12]Pasquale EB: Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat Rev Cancer 2010, 10:165-180.
• [13]Ogawa K, Pasqualini R, Lindberg RA, Kain R, Freeman AL, Pasquale EB: The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization. Oncogene 2000, 19:6043-6052.
• [14]Brantley DM, Cheng N, Thompson EJ, Lin Q, Brekken RA, Thorpe PE, Muraoka RS, Cerretti DP, Pozzi A, Jackson D, et al.: Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo. Oncogene 2002, 21:7011-7026.
• [15]Aasheim HC, Delabie J, Finne EF: Ephrin-A1 binding to CD4+ T lymphocytes stimulates migration and induces tyrosine phosphorylation of PYK2. Blood 2005, 105:2869-2876.
• [16]Easty DJ, Hill SP, Hsu MY, Fallowfield ME, Florenes VA, Herlyn M, Bennett DC: Up-regulation of ephrin-A1 during melanoma progression. Int J Cancer 1999, 84:494-501.
• [17]Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, Savagner P, Gitelman I, Richardson A, Weinberg RA: Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004, 117:927-939.
• [18]Berge G, Pettersen S, Grotterod I, Bettum IJ, Boye K, Maelandsmo GM: Osteopontin–an important downstream effector of S100A4-mediated invasion and metastasis. Int J Cancer 2011, 129:780-790.
• [19]Wai PY, Kuo PC: Osteopontin: regulation in tumor metastasis. Cancer Metastasis Rev 2008, 27:103-118.
• [20]Boldrini L, Donati V, Dell'Omodarme M, Prati MC, Faviana P, Camacci T, Lucchi M, Mussi A, Santoro M, Basolo F, Fontanini G: Prognostic significance of osteopontin expression in early-stage non-small-cell lung cancer. Br J Cancer 2005, 93:453-457.
• [21]Donati V, Boldrini L, Dell'Omodarme M, Prati MC, Faviana P, Camacci T, Lucchi M, Mussi A, Santoro M, Basolo F, Fontanini G: Osteopontin expression and prognostic significance in non-small cell lung cancer. Clin Cancer Res 2005, 11:6459-6465.
• [22]Weber GF, Lett GS, Haubein NC: Osteopontin is a marker for cancer aggressiveness and patient survival. Br J Cancer 2010, 103:861-869.
• [23]Boye K, Grotterod I, Aasheim HC, Hovig E, Maelandsmo GM: Activation of NF-kappaB by extracellular S100A4: analysis of signal transduction mechanisms and identification of target genes. Int J Cancer 2008, 123:1301-1310.
• [24]Flatmark K, Maelandsmo GM, Mikalsen SO, Nustad K, Varaas T, Rasmussen H, Meling GI, Fodstad O, Paus E: Immunofluorometric assay for the metastasis-related protein S100A4: release of S100A4 from normal blood cells prohibits the use of S100A4 as a tumor marker in plasma and serum. Tumour Biol 2004, 25:31-40.
• [25]Ishikawa M, Miyahara R, Sonobe M, Horiuchi M, Mennju T, Nakayama E, Kobayashi M, Kikuchi R, Kitamura J, Imamura N, et al.: Higher expression of EphA2 and ephrin-A1 is related to favorable clinicopathological features in pathological stage I non-small cell lung carcinoma. Lung Cancer , 76:431-438.
• [26]Ring BZ, Seitz RS, Beck RA, Shasteen WJ, Soltermann A, Arbogast S, Robert F, Schreeder MT, Ross DT: A novel five-antibody immunohistochemical test for subclassification of lung carcinoma. Mod Pathol 2009, 22:1032-1043.
• [27]Neal JW: Histology matters: individualizing treatment in non-small cell lung cancer. Oncologist 2010, 15:3-5.
• [28]Guldur ME, Kibar Y, Deniz H, Bakir K: Comparison of osteopontin, beta-catenin and hnRNP B1 expression in lung carcinomas. Pathol Oncol Res , 16:55-59.
• [29]Hu Z, Lin D, Yuan J, Xiao T, Zhang H, Sun W, Han N, Ma Y, Di X, Gao M, et al.: Overexpression of osteopontin is associated with more aggressive phenotypes in human non-small cell lung cancer. Clin Cancer Res 2005, 11:4646-4652.
• [30]Zhang J, Takahashi K, Takahashi F, Shimizu K, Ohshita F, Kameda Y, Maeda K, Nishio K, Fukuchi Y: Differential osteopontin expression in lung cancer. Cancer Lett 2001, 171:215-222.
• [31]Uozumi M, Murao S, Katayama N, Kitazawa S, Amatsu M, Maeda S: Induction of S100A4 gene expression inhibits in vitro invasiveness of human squamous cell carcinoma, KOSC-3 cells. Cancer Lett 2000, 149:135-141.
• [32]Fang Z, Duthoit N, Wicher G, Kallskog O, Ambartsumian N, Lukanidin E, Takenaga K, Kozlova EN: Intracellular calcium-binding protein S100A4 influences injury-induced migration of white matter astrocytes. Acta Neuropathol 2006, 111:213-219.
• [33]El-Naaman C, Grum-Schwensen B, Mansouri A, Grigorian M, Santoni-Rugiu E, Hansen T, Kriajevska M, Schafer BW, Heizmann CW, Lukanidin E, Ambartsumian N: Cancer predisposition in mice deficient for the metastasis-associated Mts1(S100A4) gene. Oncogene 2004, 23:3670-3680.
• [34]Massague J: TGFbeta in Cancer. Cell. 2008, 134:215-230.
• [35]Brantley-Sieders DM, Fang WB, Hwang Y, Hicks D, Chen J: Ephrin-A1 facilitates mammary tumor metastasis through an angiogenesis-dependent mechanism mediated by EphA receptor and vascular endothelial growth factor in mice. Cancer Res 2006, 66:10315-10324.
• [36]Abraham S, Knapp DW, Cheng L, Snyder PW, Mittal SK, Bangari DS, Kinch M, Wu L, Dhariwal J, Mohammed SI: Expression of EphA2 and Ephrin A-1 in carcinoma of the urinary bladder. Clin Cancer Res 2006, 12:353-360.
• [37]Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE: Ligation of EphA2 by Ephrin A1-Fc inhibits pancreatic adenocarcinoma cellular invasiveness. Biochem Biophys Res Commun 2004, 320:1096-1102.
• [38]Nakamura R, Kataoka H, Sato N, Kanamori M, Ihara M, Igarashi H, Ravshanov S, Wang YJ, Li ZY, Shimamura T, et al.: EPHA2/EFNA1 expression in human gastric cancer. Cancer Sci 2005, 96:42-47.
• [39]Nasreen N, Mohammed KA, Lai Y, Antony VB: Receptor EphA2 activation with ephrinA1 suppresses growth of malignant mesothelioma (MM). Cancer Lett 2007, 258:215-222.
• [40]Noblitt LW, Bangari DS, Shukla S, Knapp DW, Mohammed S, Kinch MS, Mittal SK: Decreased tumorigenic potential of EphA2-overexpressing breast cancer cells following treatment with adenoviral vectors that express EphrinA1. Cancer Gene Ther 2004, 11:757-766.
• [41]Lee HY, Mohammed KA, Peruvemba S, Goldberg EP, Nasreen N: Targeted lung cancer therapy using ephrinA1-loaded albumin microspheres. J Pharm Pharmacol , 63:1401-1410.
• [42]Brannan JM, Dong W, Prudkin L, Behrens C, Lotan R, Bekele BN, Wistuba I, Johnson FM: Expression of the receptor tyrosine kinase EphA2 is increased in smokers and predicts poor survival in non-small cell lung cancer. Clin Cancer Res 2009, 15:4423-4430.
• [43]Brannan JM, Sen B, Saigal B, Prudkin L, Behrens C, Solis L, Dong W, Bekele BN, Wistuba I, Johnson FM: EphA2 in the early pathogenesis and progression of non-small cell lung cancer. Cancer Prev Res (Phila) 2009, 2:1039-1049.
• [44]Wykosky J, Debinski W: The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting. Mol Cancer Res 2008, 6:1795-1806.